This Article Full Text Full Text (PDF) All Versions of this Article: 149/5/2433    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by García-Fernández, M. Articles by Castilla Cortázar, I. Search for Related Content PubMed PubMed Citation Articles by García-Fernández, M. Articles by Castilla Cortázar, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Seniors' Health

Low Doses of Insulin-Like Growth Factor I Improve Insulin Resistance, Lipid Metabolism, and Oxidative Damage in Aging Rats

Department of Physiology (M.G.-F., G.D., J.E.P., S.G.-B., I.C.C.), School of Medicine, University of Málaga, 29071 Málaga, Spain; and Department of Medical Physiology (J.E.P., I.C.C.), School of Medicine, University CEU-San Pablo, 28668 Madrid, Spain

Address all correspondence and requests for reprints to: Inma Castilla de Cortázar Larrea, M.D., Department of Medical Physiology, School of Medicine, University CEU-San Pablo, Boadilla del Monte, 28668 Madrid, Spain. E-mail: iccortazar{at}uma.es, iccortazar{at}ceu.es.

GH and IGF-I concentrations decline with age. Age-related changes appear to be linked to decreases in the anabolic hormones, GH and IGF-I. The aim of this study was to investigate the antioxidant, anabolic, and metabolic effects of the IGF-I replacement therapy, at low doses, in aging rats. Three experimental groups were included in this protocol: young healthy controls (17 wk old); untreated old (O) rats (103 wk old); and aging rats (103 wk old) treated with IGF-I during 1 month (2.25 µg IGF-I/100 g body weight^–1·d^–1). Compared with young controls, untreated aging rats showed a reduction of IGF-I and testosterone levels, and a decrease of serum total antioxidant status, which were corrected by IGF-I therapy. In addition, untreated O presented increased levels of serum glucose with hyperinsulinemia, cholesterol, and triglycerides, and a reduction of free fatty acid concentrations. IGF-I therapy was able to revert insulin resistance, and to reduce cholesterol and triglycerides levels increasing significantly free fatty acid concentrations. The O group showed higher oxidative damage in brain and liver tissues associated with alterations in antioxidant enzyme activities. IGF-I therapy reduced oxidative damage in brain and liver, normalizing antioxidant enzyme activities and mitochondrial dysfunction. In conclusion, low doses of IGF-I restore circulating IGF-I, improve glucose and lipid metabolism, increase testosterone levels and serum total antioxidant capability, and reduce oxidative damage in brain and liver associated with a normalization of antioxidant enzyme activities and mitochondrial function.